Clinical cure · participants with confirmed toenail onychomycosis
Griseofulvin showed no clear difference in clinical cure compared with azole (moderate certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Griseofulvin showed no clear difference in mycological cure compared with azole (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
It is very uncertain whether griseofulvin changes recurrence rate compared with azole (very low certainty).
1 finding from 1 review
RR 4 [0.26, 61.76]
1 study · 7 participants
Very low
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Griseofulvin may leads to lower clinical cure compared with terbinafine (low certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Griseofulvin may leads to lower mycological cure compared with terbinafine (low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with complete cure · children with tinea capitis
Complete cure and adverse events for terbinafine showed no clear difference in proportion of participants with complete cure compared with griseofulvin (low certainty).
4 findings from 1 review
RR 1.06 [0.98, 1.15]
3 studies · 328 participants
Low
RR 1.18 [0.74, 1.88]
1 study · 1006 participants
Low
RR 0.68 [0.53, 0.86]
2 studies · 334 participants
Moderate
Show 1 more finding
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for ketoconazole showed no clear difference in proportion of participants with complete cure compared with griseofulvin (low certainty).
2 findings from 1 review
Proportion of participants with complete cure · children with tinea capitis
Complete cure for fluconazole showed no clear difference in proportion of participants with complete cure compared with griseofulvin (moderate certainty).
2 findings from 1 review
Adverse events attributed to the study drugs · children with tinea capitis
Complete cure and adverse events for terbinafine showed no clear difference in adverse events attributed to the study drugs compared with griseofulvin (moderate certainty).
1 finding from 1 review
Severe adverse events · children with tinea capitis
Complete cure and adverse events for terbinafine showed no clear difference in severe adverse events compared with griseofulvin (moderate certainty).
1 finding from 1 review
Proportion of participants with complete cure · children infected with Trichophyton and Microsporum
It is very uncertain whether complete cure for itraconazole changes proportion of participants with complete cure compared with griseofulvin (very low certainty).
1 finding from 1 review